Physician profile
Nitin Kumar
NPI 1104002245
$3,508.79
in general payments reported to CMS, 2019-2025
18 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $243 · 2021: $126 · 2022: $578 · 2023: $623 · 2024: $621 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.30 |
| Education | $244.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,098.32 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $659.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $470.22 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $343.15 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $217.44 | 2022-2023 | Epclusa |
| Janssen Scientific Affairs, LLC | $123.66 | 2022 | |
| Phathom Pharmaceuticals, INC. | $116.94 | 2024 | Voquezna |
| Lilly USA, LLC | $114.88 | 2024-2025 | Omvoh |
| Medtronic USA, INC. | $109.22 | 2020 | |
| Baxter Healthcare | $60.74 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Ucb, INC. | $59.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.89 | 2023 | Dupixent |
| Janssen Pharmaceuticals, INC | $22.54 | 2020 | |
| Pacira Therapeutics, INC. | $21.52 | 2021 | |
| Pfizer INC. | $17.21 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $16.06 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.27 | 2023 | Trulance, Xifaxan |
| Intercept Pharmaceuticals, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.